|Bid||10.00 x 1400|
|Ask||13.44 x 1200|
|Day's Range||12.42 - 13.43|
|52 Week Range||11.72 - 32.20|
|Beta (3Y Monthly)||3.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.33|
Momenta Pharmaceuticals, Inc. (MNTA) today announced the publication of results from its Phase 1 study of M281 in healthy volunteers in the online edition of the peer-reviewed journal Clinical Pharmacology & Therapeutics. The paper, containing the full data from the Phase 1 study, is entitled M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics and Safety across the Full Range of IgG Reduction in a First-In-Human Study. “We are encouraged by the rapid onset and duration of target receptor occupancy, maximal reduction of circulating IgGs, and dose-dependent effect observed in this study, which demonstrates that M281 safely functions as designed in healthy volunteers and validates its mechanism,” said Santiago Arroyo, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer of Momenta Pharmaceuticals.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 6) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...
Momenta (MNTA) delivered earnings and revenue surprises of 28.57% and -13.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 65 cents. Losses, adjusted for restructuring costs, were 45 cents per share. The biotechnology company posted revenue ...
CAMBRIDGE, Mass., Nov. 07, 2018 -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided.
Momenta Pharmaceuticals, Inc. (MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights for the global launch of M923, Momenta’s proposed biosimilar to HUMIRA. Under the terms of the agreements and subject to approval by health regulatory authorities, Momenta may launch M923 in the United States (US) on November 20, 2023 and in Europe upon approval by the European Medicines Agency. Momenta plans to submit a biologics license application for M923 to the US Food and Drug Administration in the fourth quarter of 2018 and a marketing authorization application in the European Union in the first half of 2019.
Momenta Pharmaceuticals, Inc. (MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
Momenta Pharmaceuticals, Inc. (MNTA), today announced that it will release its financial results for the third quarter ended September 30, 2018 and provide a corporate update before the U.S. financial markets open on Wednesday, November 7, 2018. To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Momenta Pharmaceuticals, Inc. (MNTA) today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET. Forward-looking statements may be identified by words such as "believe," "continue," “plan to”, "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions.
Momenta's CFO, COO, general counsel and chief scientific officer are among those leaving the company.
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...
Momenta Pharmaceuticals, Inc. (MNTA) today announced the completion of its strategic review aimed at reducing costs of biosimilar development and focusing its resources on its pipeline of novel drug candidates for immune-mediated diseases. As a result, Momenta plans to advance two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to HUMIRA® and M710, its proposed biosimilar to EYLEA® being developed in collaboration with Mylan.